Molecular modulation of osteocalcin and its relevance in diabetes (Review)

International Journal of Molecular Medicine

Volumn 28, Issue 3, 2011, Pages 283-293

  Villafän Bernal, José Rafael ^a   Sánchez Enríquez, Sergio ^a   Muñoz Valle, José Francisco ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Bone; Diabetes; Insulin; Metabolism; Osteocalcin

Indexed keywords

4 CARBOXYGLUTAMIC ACID; ANTIDIABETIC AGENT; ETIRACETAM; GLUCOCORTICOID; HYDROCHLOROTHIAZIDE; LIPID; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OSTEOCALCIN; RECOMBINANT OSTEOCALCIN; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CELL INTERACTION; CELL PROLIFERATION; CONTINUOUS INFUSION; DIABETES MELLITUS; ENDOCRINE FUNCTION; EXPERIMENTAL STUDY; GENE EXPRESSION; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HISTONE ACETYLATION; HUMAN; LOW DRUG DOSE; MOLECULAR MECHANICS; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; STIMULUS RESPONSE;

1-CARBOXYGLUTAMIC ACID; ADIPONECTIN; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; GLYCEMIC INDEX; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; OSTEOCALCIN; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION, GENETIC;

EID: 79959951114     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.706     Document Type: Review

References (128)

1. Hauschka PV, Lian JB, Cole DE and Gundberg CM: Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69: 990-1047, 1989. (Pubitemid 19184853)
2. Beresford JN, Gallagher JA, Gowen M, et al: The effects of monocyte-conditioned medium and interleukin 1 on the synthesis of collagenous and non-collagenous proteins by mouse bone and human bone cells in vitro. Biochim Biophys Acta 801: 58-65, 1984. (Pubitemid 14005463)
3. Lian JB, Coutts M and Canalis E: Studies of hormonal regulation of osteocalcin synthesis in cultured fetal rat calvariae. J Biol Chem 260: 8706-8710, 1985. (Pubitemid 16239667)
4. Noda M and Rodan GA: Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect Tissue Res 21: 71-75, 1989.
5. Gaur T: Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280: 33132-33140, 2005.
6. Mundy GR and Poser JW: Chemotactic activity of the gamma-carboxyglutamic acid containing protein in bone. Calcif Tissue Int 35: 164-168, 1983. (Pubitemid 13127649)
7. Glowacki J and Lian JB: Impaired recruitment and differentiation of osteoclast progenitors by osteocalcin-deplete bone implants. Cell Differ 21: 247-254, 1987. (Pubitemid 17151359)
8. Lee NK, Sowa H, Hinoi E, et al: Endocrine regulation of energy metabolism by the skeleton. Cell 130: 456-469, 2007. (Pubitemid 47208519)
9. Pietschmann P, Schernthaner G and Woloszczuk W: Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia 31: 892-895, 1988. (Pubitemid 19054759)
10. Im JA, Yu BP, Jeon JY and Kim SH: Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta 396: 66-69, 2008.
11. Kanazawa I, Yamaguchi T, Yamamoto M, et al: Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 94: 45-49, 2009.
12. Reid IR, Chapman GE, Fraser TR, et al: Low serum osteocalcin levels in glucocorticoid-treated asthmatics. J Clin Endocrinol Metab 62: 379-383, 1986. (Pubitemid 16121571)
13. Lajeunesse D, Delalandre A and Guggino SE: Thiazide diuretics affect osteocalcin production in human osteoblasts at the transcription level without affecting vitamin D3 receptors. J Bone Miner Res 15: 894-901, 2000. (Pubitemid 30233413)
14. Kadiyala S, Nagaba S, Takeuchi K, et al: Metabolites and analogs of 1alpha, 25-dihydroxyvitamin D(3): evaluation of actions in bone. Steroids 66: 347-355, 2001. (Pubitemid 32140912)
15. Vazquez G, Santillan G, Boland R, Roldan E and Perez-Lloret A: Modulation of cytosolic calcium levels in osteoblast-like osteosarcoma cells by olpadronate and its amino-derivative IG-9402. Calcif Tissue Int 72: 215-221, 2003. (Pubitemid 36919526)
16. Celeste AJ, Rosen V, Buecker JL, Kriz R, Wang EA and Wozney JM: Isolation of the human gene for bone gla protein utilizing mouse and rat cDNA clones. EMBO J 5: 1885-1890, 1986.
17. Hoffmann HM, Catron KM, van Wijnen AJ, et al: Transcriptional control of the tissue-specific, developmentally regulated osteocalcin gene requires a binding motif for the Msx family of homeodomain proteins. Proc Natl Acad Sci USA 91: 12887-12891, 1994.
18. Banerjee C, Stein JL, van Wijnen AJ, Frenkel B, Lian JB and Stein GS: Transforming growth factor-beta 1 responsiveness of the rat osteocalcin gene is mediated by an activator protein-1 binding site. Endocrinology 137: 1991-2000, 1996.
19. Stein GS, Lian JB, van Wijnen AJ and Stein JL: The osteocalcin gene: a model for multiple parameters of skeletal-specific transcriptional control. Mol Biol Rep 24: 185-196, 1997. (Pubitemid 27358372)
20. Franceschi RT: The developmental control of osteoblast-specific gene expression: role of specific transcription factors and the extracellular matrix environment. Crit Rev Oral Biol Med 10: 40-57, 1999.
21. Aslam F, McCabe L, Frenkel B, et al: AP-1 and vitamin D receptor (VDR) signaling pathways converge at the rat osteocalcin VDR element: requirement for the internal activating protein-1 site for vitamin D-mediated trans-activation. Endocrinology 140: 63-70, 1999. (Pubitemid 29011142)
22. Willis DM, Loewy AP, Charlton-Kachigian N, Shao JS, Ornitz DM and Towler DA: Regulation of osteocalcin gene expression by a novel Ku antigen transcription factor complex. J Biol Chem 277: 37280-37291, 2002.
23. Xiao G, Jiang D, Gopalakrishnan R and Franceschi RT: Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. J Biol Chem 277: 36181-36187, 2002.
24. Jung C, Ou YC, Yeung F, Frierson HF Jr and Kao C: Osteocalcin is incompletely spliced in non-osseous tissues. Gene 271: 143-150, 2001. (Pubitemid 32545391)
25. Lian JB and Stein GS: Development of the osteoblast phenotype: molecular mechanisms mediating osteoblast growth and differentiation. Iowa Orthop J 15: 118-140, 1995.
26. Frenkel B, Montecino M, Green J, et al: Basal and vitamin D-responsive activity of the rat osteocalcin promoter in stably transfected osteosarcoma cells: requirement of upstream sequences for control by the proximal regulatory domain. Endocrinology 137: 1080-1088, 1996. (Pubitemid 26070388)
27. Shen J: Histone acetylation in vivo at the osteocalcin locus is functionally linked to vitamin D-dependent, bone tissue-specific transcription. J Biol Chem 277: 20284-20292, 2002.
28. Schroeder TM, Kahler RA, Li X and Westendorf JJ: Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem 279: 41998-42007, 2004. (Pubitemid 39313651)
29. Blanco JC, Wang IM, Tsai SY, et al: Transcription factor TFIIB and the vitamin D receptor cooperatively activate ligand-dependent transcription. Proc Natl Acad Sci USA 92: 1535-1539, 1995.
30. Javed A, Gutierrez S, Montecino M, et al: Multiple Cbfa/AML sites in the rat osteocalcin promoter are required for basal and vitamin D-responsive transcription and contribute to chromatin organization. Mol Cell Biol 19: 7491-7500, 1999. (Pubitemid 29493412)
31. Sierra J, Villagra A, Paredes R, et al: Regulation of the bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity. Mol Cell Biol 23: 3339-3351, 2003. (Pubitemid 36459245)
32. Yu S, Jiang Y, Galson DL, et al: General transcription factor IIA-gamma increases osteoblast-specific osteocalcin gene expression via activating transcription factor 4 and runt-related transcription factor 2. J Biol Chem 283: 5542-5553, 2008.
33. Paredes R, Arriagada G, Cruzat F, et al: Bone-specific transcription factor Runx2 interacts with the 1alpha, 25-dihydroxyvitamin D3 receptor to up-regulate rat osteocalcin gene expression in osteoblastic cells. Mol Cell Biol 24: 8847-8861, 2004. (Pubitemid 39313891)
34. Hassan MQ, Javed A, Morasso MI, et al: Dlx3 transcriptional regulation of osteoblast differentiation: temporal recruitment of Msx2, Dlx3, and Dlx5 homeodomain proteins to chromatin of the osteocalcin gene. Mol Cell Biol 24: 9248-9261, 2004.
35. Shirakabe K, Terasawa K, Miyama K, Shibuya H and Nishida E: Regulation of the activity of the transcription factor Runx2 by two homeobox proteins, Msx2 and Dlx5 Genes Cells 6: 851-856, 2001. (Pubitemid 33019738)
36. Newberry EP, Latifi T and Towler DA: Reciprocal regulation of osteocalcin transcription by the homeodomain proteins Msx2 and Dlx5 Biochemistry 37: 16360-16368, 1998.
37. Stromstedt PE, Poellinger L, Gustafsson JA and Carlstedt-Duke J: The glucocorticoid receptor binds to a sequence overlapping the TATA box of the human osteocalcin promoter: a potential mechanism for negative regulation. Mol Cell Biol 11: 3379-3383, 1991.
38. Meyer T, Carlstedt-Duke J and Starr DB: A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene. J Biol Chem 272: 30709-30714, 1997. (Pubitemid 27527504)
39. Stein GS, Lian JB, Dworetzky SI, et al: Regulation of transcription-factor activity during growth and differentiation: involvement of the nuclear matrix in concentration and localization of promoter binding proteins. J Cell Biochem 47: 300-305, 1991.
40. Bidwell JP, van Wijnen AJ, Fey EG, et al: Osteocalcin gene promoter-binding factors are tissue-specific nuclear matrix components. Proc Natl Acad Sci USA 90: 3162-3166, 1993. (Pubitemid 23111325)
41. Pan LC and Price PA: The propeptide of rat bone gamma-carboxyglutamic acid protein shares homology with other vitamin K-dependent protein precursors. Proc Natl Acad Sci USA 82: 6109-6113, 1985. (Pubitemid 16223908)
42. Jorgensen MJ, Cantor AB, Furie BC, Brown CL, Shoemaker CB and Furie B: Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX. Cell 48: 185-191, 1987.
43. Poser JW, Esch FS, Ling NC and Price PA: Isolation and sequence of the vitamin K-dependent protein from human bone. Undercarboxylation of the first glutamic acid residue. J Biol Chem 255: 8685-8691, 1980.
44. Nishimoto SK, Chang CH, Gendler E, Stryker WF and Nimni ME: The effect of aging on bone formation in rats: biochemical and histological evidence for decreased bone formation capacity. Calcif Tissue Int 37: 617-624, 1985. (Pubitemid 16197171)
45. Moreau R, Aubin R, Lapointe JY and Lajeunesse D: Pharmacological and biochemical evidence for the regulation of osteocalcin secretion by potassium channels in human osteoblast-like MG-63 cells. J Bone Miner Res 12: 1984-1992, 1997.
46. Eliasson L, Abdulkader F, Braun M, Galvanovskis J, Hoppa MB and Rorsman P: Novel aspects of the molecular mechanisms controlling insulin secretion. J Physiol 586: 3313-3324, 2008. (Pubitemid 352003868)
47. Pavlin D, Zadro R and Gluhak-Heinrich J: Temporal pattern of stimulation of osteoblast-associated genes during mechanically-induced osteogenesis in vivo: early responses of osteocalcin and type I collagen. Connect Tissue Res 42: 135-148, 2001. (Pubitemid 33040400)
48. Rath B, Nam J, Knobloch TJ, Lannutti JJ and Agarwal S: Compressive forces induce osteogenic gene expression in calvarial osteoblasts. J Biomech 41: 1095-1103, 2008.
49. Akhouayri O, Lafage-Proust MH, Rattner A, et al: Effects of static or dynamic mechanical stresses on osteoblast phenotype expression in three-dimensional contractile collagen gels. J Cell Biochem 76: 217-230, 1999. (Pubitemid 30030770)
50. Tanaka SM, Li J, Duncan RL, Yokota H, Burr DB and Turner CH: Effects of broad frequency vibration on cultured osteoblasts. J Biomech 36: 73-80, 2003. (Pubitemid 35448095)
51. Franceschi RT and Xiao G: Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 88: 446-454, 2003. (Pubitemid 36158266)
52. Johnson ML and Kamel MA: The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 19: 376-382, 2007. (Pubitemid 46884195)
53. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127 469-480, 2006.
54. Baron R and Rawadi G: Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148: 2635-2643, 2007. (Pubitemid 46984775)
55. Case N, Ma M, Sen B, Xie Z, Gross TS and Rubin J: Beta-catenin levels influence rapid mechanical responses in osteoblasts. J Biol Chem 283: 29196-29205, 2008.
56. Manolagas SC: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115-137, 2000.
57. Stupack DG and Cheresh DA: Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 115: 3729-3738, 2002. (Pubitemid 35203599)
58. Takeuchi Y, Suzawa M, Kikuchi T, Nishida E, Fujita T and Matsumoto T: Differentiation and transforming growth factor-beta receptor down-regulation by collagen-alpha2beta1 integrin interaction is mediated by focal adhesion kinase and its down-stream signals in murine osteoblastic cells. J Biol Chem 272: 29309-29316, 1997. (Pubitemid 27498224)
59. Xiao G, Wang D, Benson MD, Karsenty G and Franceschi RT: Role of the alpha2-integrin in osteoblast-specific gene expression and activation of the Osf2 transcription factor. J Biol Chem 273: 32988-32994, 1998. (Pubitemid 28557693)
60. DAlonzo RC, Kowalski AJ, Denhardt DT, Nickols GA and Partridge NC: Regulation of collagenase-3 and osteocalcin gene expression by collagen and osteopontin in differentiating MC3T3-E1 cells. J Biol Chem 277: 24788-24798, 2002. (Pubitemid 34952011)
61. Mizuno M and Kuboki Y: Osteoblast-related gene expression of bone marrow cells during the osteoblastic differentiation induced by type I collagen. J Biochem 129: 133-138, 2001. (Pubitemid 32150490)
62. Moursi AM, Globus RK and Damsky CH: Interactions between integrin receptors and fibronectin are required for calvarial osteoblast differentiation in vitro. J Cell Sci 110: 2187-2196, 1997. (Pubitemid 27448363)
63. Rizzino A: Understanding the roles of growth factors in carcinogenesis: modulation of autocrine growth control by differentiation. Int J Dev Biol 37: 61-65, 1993.
64. Pirskanen A, Jaaskelainen T and Maenpaa PH: Insulin-like growth factor-1 modulates steroid hormone effects on osteocalcin synthesis in human MG-63 osteosarcoma cells. Eur J Biochem 218: 883-891, 1993. (Pubitemid 24010054)
65. Maliakal JC, Asahina I, Hauschka PV and Sampath TK: Osteogenic protein-1 (BMP-7) inhibits cell proliferation and stimulates the expression of markers characteristic of osteoblast phenotype in rat osteosarcoma (17/2.8) cells. Growth Factors 11: 227-234, 1994.
66. Staal A, Geertsma-Kleinekoort WM, van Den Bemd GJ, et al: Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: interaction with the bone-derived growth factors TGF-beta and IGF-I. J Bone Miner Res 13: 36-43, 1998. (Pubitemid 28063111)
67. Schedlich LJ, Flanagan JL, Crofts LA, et al: Transcriptional activation of the human osteocalcin gene by basic fibroblast growth factor. J Bone Miner Res 9: 143-152, 1994. (Pubitemid 24041559)
68. Samee M, Kasugai S, Kondo H, Ohya K, Shimokawa H and Kuroda S: Bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) transfection to human periosteal cells enhances osteoblast differentiation and bone formation. J Pharmacol Sci 108: 18-31, 2008.
69. Chen D, Harris MA, Rossini G, et al: Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif Tissue Int 60: 283-290, 1997.
70. Chen D, Zhao M and Mundy GR: Bone morphogenetic proteins. Growth Factors 22: 233-241, 2004. (Pubitemid 40136452)
71. Takagi M, Kamiya N, Takahashi T, et al: Effects of bone morphogenetic protein-2 and transforming growth factor beta1 on gene expression of transcription factors, AJ18 and Runx2 in cultured osteoblastic cells. J Mol Histol 35: 81-90, 2004. (Pubitemid 40585338)
72. Phimphilai M, Zhao Z, Boules H, Roca H and Franceschi RT: BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype. J Bone Miner Res 21: 637-646, 2006.
73. Sowa H: Menin is required for bone morphogenetic protein 2- and transforming growth factor-regulated osteoblastic differentiation through interaction with Smads and Runx2. J Biol Chem 279: 40267-40275, 2004.
74. Yu XP and Chandrasekhar S: Parathyroid hormone (PTH 1-34) regulation of rat osteocalcin gene transcription. Endocrinology 138: 3085-3092, 1997.
75. Yu S, Franceschi RT, Luo M, et al: Parathyroid hormone increases activating transcription factor 4 expression and activity in osteoblasts: requirement for osteocalcin gene expression. Endocrinology 149: 1960-1968, 2008.
76. Kobayashi T, Sugimoto T, Saijoh K, Fukase M and Chihara K: Calcitonin directly acts on mouse osteoblastic MC3T3-E1 cells to stimulate mRNA expression of c-fos, insulin-like growth factor-1 and osteoblastic phenotypes (type 1 collagen and osteocalcin). Biochem Biophys Res Commun 199: 876-880, 1994. (Pubitemid 24181743)
77. Gordeladze JO, Drevon CA, Syversen U and Reseland JE: Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: Impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem 85: 825-836, 2002.
78. Jenis LG, Ongphiphadhanakul B, Braverman LE, et al: Responsiveness of gene expression markers of osteoblastic and osteoclastic activity to calcitonin in the appendicular and axial skeleton of the rat in vivo. Calcif Tissue Int 54: 511-515, 1994. (Pubitemid 24148215)
79. Ducy P, Amling M, Takeda S, et al: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197-207, 2000. (Pubitemid 30064908)
80. Hinoi E, Gao N, Jung DY, et al: The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity J Cell Biol 183: 1235-1242, 2008.
81. Juppner H, Abou-Samra AB, Freeman M, et al: A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254: 1024-1026, 1991. (Pubitemid 21917436)
82. Boguslawski G, Hale LV, Yu XP, et al: Activation of osteocalcin transcription involves interaction of protein kinase A- and protein kinase C-dependent pathways. J Biol Chem 275: 999-1006, 2000. (Pubitemid 30051146)
83. Mordret G: MAP kinase kinase: a node connecting multiple pathways. Biol Cell 79: 193-207, 1993.
84. Pelech SL, Charest DL, Mordret GP, et al: Networking with mitogen-activated protein kinases. Mol Cell Biochem 127-128: 157-169, 1993.
85. Xiao G, Jiang D, Thomas P, et al: MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem 275: 4453-4459, 2000. (Pubitemid 30094689)
86. Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912, 2002.
87. Owen TA, Bortell R, Shalhoub V, et al: Postproliferative transcription of the rat osteocalcin gene is reflected by vitamin D-responsive developmental modifications in protein-DNA interactions at basal and enhancer promoter elements. Proc Natl Acad Sci USA 90: 1503-1507, 1993. (Pubitemid 23058201)
88. Leclerc N, Noh T, Khokhar A, Smith E and Frenkel B: Glucocorticoids inhibit osteocalcin transcription in osteoblasts by suppressing Egr2/Krox20-binding enhancer. Arthritis Rheum 52: 929-939, 2005. (Pubitemid 40365117)
89. Oliva A, Delia Ragione F, Fratta M, Marrone G, Palumbo R and Zappia V: Effect of retinoic acid on osteocalcin gene expression in human osteoblasts. Biochem Biophys Res Commun 191: 908-914, 1993. (Pubitemid 23231576)
90. Kawano S, Kambe F, Ohmori S, Kanda K, Nagaya T and Seo H: Effect of estrogen and tail-suspension on expression of osteocalcin mRNA in femur of ovariectomized rats. Environ Med 44: 82-84, 2000.
91. Robinson JA, Harris SA, Riggs BL and Spelsberg TC: Estrogen regulation of human osteoblastic cell proliferation and differentiation. Endocrinology 138: 2919-2927, 1997.
92. Chen L and Foged NT: Induction of osteocalcin gene expression in vitro by progesterone. J Tongji Med Univ 17: 72-74, 1997.
93. Varga F, Rumpier M, Luegmayr E, Fratzl-Zelman N, Glantschnig H and Klaushofer K: Triiodothyronine, a regulator of osteoblastic differentiation: depression of histone H4, attenuation of c-fos/c-jun, and induction of osteocalcin expression. Calcif Tissue Int 61: 404-411, 1997. (Pubitemid 27507907)
94. Schrader M, Bendik I, Becker-Andre M and Carlberg C: Interaction between retinoic acid and vitamin D signaling pathways. J Biol Chem 268: 17830-17836, 1993. (Pubitemid 23260293)
95. Morrison NA, Shine J, Fragonas JC, Verkest V, McMenemy ML and Eisman JA: 1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science 246: 1158-1161, 1989. (Pubitemid 20012774)
96. Aslam F, Shalhoub V, van Wijnen AJ, et al: Contributions of distal and proximal promoter elements to glucocorticoid regulation of osteocalcin gene transcription. Mol Endocrinol 9: 679-690, 1995.
97. Rickard DJ, Subramaniam M and Spelsberg TC: Molecular and cellular mechanisms of estrogen action on the skeleton. J Cell Biochem 75 (Suppl 32-33): S123-S132, 1999.
98. Notoya K, Nagai H, Oda T, et al: Enhancement of osteogenesis in vitro and in vivo by a novel osteoblast differentiation promoting compound, TAK-778. J Pharmacol Exp Ther 290: 1054-1064, 1999. (Pubitemid 29400244)
99. Morabito N, Crisafulli A, Vergara C, et al: Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 17: 1904-1912, 2002.
100. Lukert BP, Higgins JC and Stoskopf MM: Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J Clin Endocrinol Metab 62: 1056-1058, 1986. (Pubitemid 16106741)
101. Viereck V, Siggelkow H, Tauber S, Raddatz D, Schutze N and Hufner M: Differential regulation of Cbfal/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts. J Cell Biochem 86: 348-356, 2002. (Pubitemid 34743391)
102. Nissen-Meyer LS, Svalheim S, Tauboll E, et al: Levetiracetam, Phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 48: 1850-1860, 2007.
103. Hauschka PV and Reid ML: Vitamin D dependence of a calcium-binding protein containing gamma-carboxyglutamic acid in chicken bone. J Biol Chem 253: 9063-9068, 1978. (Pubitemid 9117021)
104. Ducy P, Geoffroy V and Karsenty G: Study of osteoblast-specific expression of one mouse osteocalcin gene: characterization of the factor binding to OSE2. Connect Tissue Res 35: 7-14, 1996. (Pubitemid 27118832)
105. Murshed M: Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 165: 625-630, 2004.
106. Ferron M, Hinoi E, Karsenty G and Ducy P: Osteocalcin differentially regulates cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105: 5266-5270, 2008. (Pubitemid 351738545)
107. Kruse K and Kracht U: Evaluation of serum osteocalcin as an index of altered bone metabolism. Eur J Pediatr 145: 27-33, 1986. (Pubitemid 16097662)
108. Rosato MT, Schneider SH and Shapses SA: Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif Tissue Int 63: 107-111, 1998. (Pubitemid 28347682)
109. Akin O, Gol K, Akturk M and Erkaya S: Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements. Gynecol Endocrinol 17: 19-29, 2003. (Pubitemid 36349878)
110. Achemlal L, Tellal S, Rkiouak F, et al: Bone metabolism in male patients with type 2 diabetes. Clin Rheumatol 24: 493-496, 2005. (Pubitemid 43055041)
111. Dobnig H, Piswanger-Solkner JC, Roth M, et al: Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 91: 3355-3363, 2006. (Pubitemid 44402104)
112. Cutrim DM, Pereira FA, de Paula FJ and Foss MC: Lack of relationship between glycemic control and bone mineral density in type 2 diabetes mellitus. Braz J Med Biol Res 40: 221-227, 2007. (Pubitemid 46237854)
113. Nagasaka S, Murakami T, Uchikawa T, Ishikawa SE and Saito T: Effect of glycemic control on calcium and phosphorus handling and parathyroid hormone level in patients with non-insulin-dependent diabetes mellitus. Endocr J 42: 377-383, 1995.
114. Sayinalp S, Gedik O and Koray Z: Increasing serum osteocalcin after glycemic control in diabetic men. Calcif Tissue Int 57: 422-425, 1995.
115. Guarneri MP, Weber G, Gallia P and Chiumello G: Effect of insulin treatment on osteocalcin levels in diabetic children and adolescents. J Endocrinol Invest 16: 505-509, 1993. (Pubitemid 23275974)
116. Hwang YC, Jeong IK, Ahn KJ and Chung HY: The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev 25: 768-772, 2009.
117. Shea MK, Gundberg CM, Meigs JB, et al: Gamma-carboxylation of osteocalcin and insulin resistance in older men and women. Am J Clin Nutr 90: 1230-1235, 2009.
118. Pittas AG, Harris SS, Eliades M, Stark P and Dawson-Hughes B: Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 94: 827-832, 2009.
119. Clore JN and Thurby-Hay L: Glucocorticoid-induced hyperglycemia. Endocr Pract 15: 469-474, 2009.
120. Sowers JR, Raij L, Jialal I, et al: Angiotensin receptor blocker/ diuretic combination preserves insulin responses in obese hypertensives. J Hypertens 28: 1761-1769, 2010.
121. Moller DE: New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414: 821-827, 2001.
122. Zhang ZY and Lee SY: PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin Investig Drugs 12: 223-233, 2003.
123. Hiromura M, Nakayama A, Adachi Y, Doi M and Sakurai H: Action mechanism of bis(allixinato)oxovanadium(IV) as a novel potent insulin-mimetic complex: regulation of GLUT4 translocation and FoxO1 transcription factor. J Biol Inorg Chem 12: 1275-1287, 2007.
124. Wang ZQ, Ribnicky D, Zhang XH, Raskin I, Yu Y and Cefalu WT: Bioactives of Artemisia dracunculus L enhance cellular insulin signaling in primary human skeletal muscle culture. Metabolism 57 (Suppl 1): S58-S64, 2008. (Pubitemid 351814703)
125. Virally M, Blickle JF, Girard J, Halimi S, Simon D and Guillausseau PJ: Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab 33: 231-244, 2007. (Pubitemid 47440080)
126. Villafán-Bernal JR, Munoz-Valle JF, Llamas-Covarrubias MA and Sanchez-Enriquez S: Relationship of uncarboxylated osteocalcin concentrations and ucOC/cOC index with the glycemic status in type 2 diabetes mellitus. Bone 46: S56, 2010.
127. Inaba M, Terada M, Koyama H, et al: Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res 10: 1050-1056, 1995.
128. Okazaki R, Totsuka Y, Hamano K, et al: Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 82: 2915-2920, 1997. (Pubitemid 27385648)